RECOVERY & TISSUE REPAIR / FAQ
Questions From the Research-Use Community
Direct, citation-anchored answers to what people actually ask about these seven repair peptides.
What does BPC-157 do in the body?
In animal studies, BPC-157 is most consistently linked to angiogenesis — it up-regulates the VEGFR2 receptor and switches on a VEGFR2-Akt-eNOS signaling chain that grows new blood vessels into damaged tissue, which researchers believe underlies its effects on healing tendons, gut lining, and other injured tissue [4]. Other proposed mechanisms include a FAK-paxillin pathway tied to cell migration and modulation of nitric-oxide and neurotransmitter systems [7]. Almost all of this evidence comes from rats, dogs, and cell studies; a 2025 first-in-human safety pilot found no adverse events at doses up to 20 mg, but that trial had only two participants and measured safety, not effectiveness [1].
Does BPC-157 damage the liver?
The best available human safety data says no measurable harm was detected, but that data is extremely limited. A 2025 pilot study gave two healthy adults intravenous BPC-157 up to 20 mg and found no measurable changes in hepatic (liver), renal, cardiac, thyroid, or glucose biomarkers [1]. That's reassuring as far as it goes, but an n of two cannot rule out rare or longer-term liver effects, and a 2025 review is explicit that rigorous large-scale human trials, the kind that would actually detect an uncommon liver signal, simply haven't been done [2]. Treat this as no signal found yet in a very small sample, not as a cleared safety profile.
What is TB-500 used for in research?
TB-500 (Ac-LKKTETQ) is studied as a synthetic fragment of thymosin beta-4, a protein involved in cell migration, wound healing, and reduced scar formation. Most of the actual research supporting these effects, including the one published human trial, used the full-length parent protein, not the short fragment sold as TB-500, so the fragment's own effects are less directly established [10][11]. A 2026 review of unapproved musculoskeletal peptides names TB-500 among compounds showing favorable animal-model tissue-repair outcomes, alongside a caution that human safety data remain scarce [8].
Does TB-500 work for muscle tears and recovery from exercise?
There's no controlled human trial testing TB-500 for muscle-tear or exercise recovery specifically. What exists is animal and mechanistic research on the parent protein, thymosin beta-4 is documented to reduce myofibroblast (scar-tissue) formation and promote cell migration in injury models [10], plus a large body of anecdotal community reporting that is explicitly not clinical evidence. A 2026 review of unapproved peptides for musculoskeletal injuries and athletic performance concludes the category shows promise in animal models but that rigorous human safety and efficacy data are lacking [8].
What is GHK-Cu and how does it work?
GHK-Cu is a copper-chelated tripeptide, glycyl-L-histidyl-L-lysine bound to a copper ion, that occurs naturally in the body and declines with age. It stimulates dermal fibroblasts to produce collagen, elastin, and other matrix proteins, and a 2018 gene-expression analysis found it modulates roughly 31.2% of measured human genes, tilted toward tissue-repair, antioxidant, and DNA-repair programs [14]. Most of its controlled human evidence is topical, applied to skin, rather than injected [13][16].
Is GHK-Cu peptide really anti-aging?
For topical use, there's real controlled human trial support: a 2025 review found procollagen synthesis increased in 70% of GHK-Cu-treated subjects, versus 50% for vitamin C and 40% for retinoic acid, two well-established comparators [13]. A 2015 review documents placebo-controlled improvements in skin laxity, clarity, fine lines, and wrinkle depth [16]. That's a genuinely stronger evidence base than most compounds on this site. It doesn't mean unlimited anti-aging claims are supported; the studies measure specific, modest outcomes over defined trial periods, not a general reversal of aging.
What is KPV peptide used for?
KPV is studied mainly in animal models of gut inflammation, particularly colitis. It's a fragment of alpha-MSH that keeps the parent hormone's anti-inflammatory activity, suppressing NF-kB signaling, while dropping its pigment-darkening effect [20][22]. Recent research has focused on delivery: a 2024 study built a PepT1-targeted nanodrug pairing KPV with an immunosuppressant that improved outcomes in mice with both acute and chronic colitis [18]. There are no published human clinical trials of KPV for this or any use.
What is the Wolverine peptide blend?
Wolverine is a research-community name for a combination of two separate peptides, BPC-157 and TB-500, sold together in one vial. The pairing is meant to combine BPC-157's blood-vessel-growth mechanism with TB-500's cell-migration mechanism [4][10]. No controlled study, animal or human, has ever tested the combination itself; a 2025 systematic review of BPC-157 in sports medicine, covering 36 studies, doesn't mention TB-500 or any combination [23].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is mechanistic complementarity: BPC-157 is studied for growing new blood vessels into injured tissue via the VEGFR2-Akt-eNOS pathway [4], while TB-500's parent protein is studied for helping cells physically migrate into a wound by binding and releasing actin [10]. Two different jobs in the repair process, covered by two different peptides, that's the theory. It has not been tested as a combined product in any published study, so why they're combined is currently a hypothesis about mechanism, not a demonstrated result about the pairing.
What is KLOW peptide used for?
KLOW is a four-peptide research blend, KPV, GHK-Cu, BPC-157, and TB-500, combined on the theory that it covers inflammation-suppression, matrix-building, blood-vessel growth, and cell migration in one product. Each ingredient has its own individually-studied mechanism [14][20][1]. No study has tested the four-peptide combination itself against its parts, a subset, or a placebo, so any claim about what KLOW specifically does is an extrapolation from the separate ingredient research, not a direct finding.
What is GLOW peptide?
GLOW is a three-peptide research blend, typically GHK-Cu, BPC-157, and TB-500, commonly described in research communities with more emphasis on skin appearance than Wolverine, its two-ingredient relative. GHK-Cu is usually the largest share by weight, around 50 of an 80 mg vial in a commonly cited recipe. A 2026 review naming all three ingredients together concludes they show promise in animal models but that rigorous human safety data remain scarce [8].
What peptides are in the GLOW blend?
The three most commonly listed ingredients are GHK-Cu, a copper-carrying tripeptide, usually the largest share by weight, BPC-157, a gastric-derived pentadecapeptide, and TB-500, the actin-binding fragment of thymosin beta-4. A commonly cited research-label ratio is 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 per vial, though ratios vary by supplier and are not standardized or independently verified [16][4].